Tresiba (Insulin Degludec) Patent Field and When a Generic Might Arrive

What Is Insulin Degludec and How Does It Work?

Insulin degludec is an ultra-long-acting basal insulin analog engineered to act for more than 42 hours after a single subcutaneous injection. It controls fasting and between-meal glucose without the pronounced peak that older basal insulins produce. For women whose glucose is destabilized by hormonal fluctuations across the menstrual cycle or during perimenopause, a flat, predictable insulin profile matters more than most clinicians discuss.

The Molecular Engineering Behind the Long Duration

The structure of insulin degludec differs from human insulin at two points. The amino acid threonine at position B30 has been removed, and a 16-carbon fatty diacid chain (hexadecandioic acid) is attached to lysine B29 via a glutamic acid linker and a mini-PEG spacer. After subcutaneous injection, degludec monomers self-assemble into soluble multihexamers that bind depot zinc and fatty acids in subcutaneous tissue, forming a subcutaneous depot. Monomers then dissociate slowly and continuously from the depot into the bloodstream, producing a flat pharmacokinetic profile with no discernible peak after steady state is reached at approximately three days of once-daily dosing.

Why a Flat Profile Matters for Women

Women with type 1 diabetes experience well-documented insulin resistance during the luteal phase of the menstrual cycle, driven by rising progesterone and, to a lesser extent, estrogen. A basal insulin with variable absorption kinetics can amplify this already-difficult period. In clinical pharmacology studies, degludec showed approximately four times lower day-to-day variability in glucose-lowering effect compared with glargine U-100, which may translate to more predictable control across the hormone-driven glucose swings of the cycle.

During perimenopause, erratic estrogen fluctuations alter insulin sensitivity unpredictably. A less variable basal insulin does not eliminate this problem, but it removes one variable. Postmenopausal women with type 2 diabetes tend to have more stable hormonal environments but often carry more visceral adiposity, increasing overall insulin requirements. The dose flexibility of degludec (it can be shifted up to 8 hours earlier or later without loss of efficacy) makes once-daily dosing practical regardless of schedule disruptions, a real benefit for shift workers and caregivers.

The DEVOTE Trial: What the Evidence Actually Shows

The DEVOTE trial, published in the New England Journal of Medicine in 2017, is the key cardiovascular outcomes trial for insulin degludec. The trial enrolled 7,637 patients with type 2 diabetes at high cardiovascular risk and randomized them to degludec or glargine U-100 in a double-blind, treat-to-target design. Roughly 36 percent of participants were women. The headline results:

• Cardiovascular safety: Degludec was non-inferior to glargine for major adverse cardiovascular events (MACE): hazard ratio 0.91, 95% CI 0.78 to 1.06, p < 0.001 for non-inferiority. DEVOTE NEJM 2017.
• Nocturnal hypoglycemia: Confirmed nocturnal symptomatic hypoglycemia was 54 percent lower with degludec than with glargine (rate ratio 0.46, 95% CI 0.38 to 0.56, p < 0.001).
• Severe hypoglycemia: Severe hypoglycemia rates were also significantly lower with degludec (rate ratio 0.60, p < 0.001).

The sex-disaggregated DEVOTE data were not reported as primary endpoints. That gap in reporting is a known problem across major diabetes outcomes trials. Women represent roughly one-third of most large cardiovascular outcomes trial cohorts in diabetes, yet results are rarely stratified by sex as a primary analysis. The DEVOTE sub-study DEVOTE 2, published in Diabetes Care, examined hypoglycemia and cardiovascular events but did not stratify by menopausal status or menstrual cycle phase, underscoring how much female-specific physiology remains unstudied in this area.

What DEVOTE Means for Women Specifically

Women have a higher relative cardiovascular risk from diabetes than men do. The excess cardiovascular risk conferred by type 2 diabetes is approximately 44 percent greater in women than in men, a fact that makes cardiovascular safety data for any antidiabetic drug particularly consequential for female patients. The nocturnal hypoglycemia reduction in DEVOTE is clinically significant for women who are sole caregivers and cannot afford to have their sleep disrupted by hypoglycemic episodes, or for those whose hypoglycemia awareness is blunted by estrogen loss in menopause.

Tresiba Patent Field: A Practical Guide

Patents for biologic drugs are not a single fence. Novo Nordisk has built a layered structure of intellectual property around insulin degludec that separates the original molecule patent from formulation patents and device patents. Understanding each layer explains why the word "generic" rarely applies here, and why "biosimilar" is the more accurate term.

Layer 1: Composition-of-Matter Patent

The foundational US patent covering the degludec molecule itself expired in 2022. In theory, this is the most important expiry. In practice, it is necessary but not sufficient for a biosimilar launch, because the formulation and delivery-device patents remain active.

Layer 2: Formulation Patents

Novo Nordisk holds multiple US formulation patents covering the specific phenol, zinc, glycerol, and acetate composition of the Tresiba injectable solution, and the concentration-specific formulations (100 units/mL and 200 units/mL). Several of these formulation patents extend to approximately 2027 to 2029 based on the Purple Book listing for degludec. A biosimilar manufacturer must either design around these formulations, challenge them through inter partes review (IPR) at the US Patent and Trademark Office, or wait for expiry.

Layer 3: Device and Delivery Patents

Tresiba is delivered via the FlexTouch pen, a device with its own patent estate. Delivery device patents are frequently the longest-lived in insulin IP portfolios. The FlexTouch device patents extend into the late 2020s, with some claims potentially reaching past 2030. A biosimilar that uses a different delivery mechanism would need separate FDA approval for that device and would face its own regulatory pathway.

Layer 4: Pediatric Exclusivity and Market Exclusivity

The FDA granted Tresiba six months of pediatric exclusivity in addition to the 12-year biologic exclusivity period under the Biologics Price Competition and Innovation Act (BPCIA). The 12-year exclusivity ran from the September 2015 approval date, expiring in September 2027. Until that date, the FDA cannot approve an interchangeable biosimilar even if all patents have been resolved. The FDA Purple Book lists Tresiba's biologic exclusivity end date, which biosimilar applicants must track.

Realistic Biosimilar Timeline

Combining all four layers, the realistic US timeline for an interchangeable insulin degludec biosimilar is 2028 to 2030. No biosimilar application for degludec was listed in the FDA's Purple Book as approved or pending as of the date of this article. In Europe, where the regulatory pathway differs and exclusivity periods are shorter, biosimilar competition may arrive earlier, but that does not affect US pricing. For a woman paying out-of-pocket or on a high-deductible plan, this means Tresiba's current list price (approximately $530 per 5-pen box in the US) will likely remain elevated for several more years.

What Novo Nordisk's Own Biosimilar Strategy Means for You

Novo Nordisk has launched lower-list-price insulins through its authorized generic affiliate, cutting the list price of some insulin products by up to 78 percent for other formulations. Whether a similar strategy will apply to Tresiba before the formal biosimilar window is not confirmed. Manufacturer patient assistance programs (Novo Nordisk Patient Assistance Program) and the $35 insulin cap for Medicare Part D beneficiaries under the Inflation Reduction Act of 2022 are the main cost-mitigation tools available to you right now.

Who This Basal Insulin Is Right For (and Who Should Think Carefully)

Women Who May Benefit Most

• Type 1 diabetes across reproductive years: The lower day-to-day variability may help women manage the luteal-phase insulin resistance that disrupts control each cycle. However, the clinical trials were conducted predominantly in type 2 diabetes populations, so this benefit is partly extrapolated from PK/PD data.
• Type 2 diabetes with nocturnal hypoglycemia history: The 54 percent reduction in nocturnal events seen in DEVOTE is the strongest practical differentiator from glargine.
• Women with irregular schedules: The up-to-8-hour dose-timing flexibility accommodates shift work, parenting disruptions, and the schedule unpredictability of the postpartum period.
• Perimenopausal and postmenopausal women with high cardiovascular risk: The non-inferior MACE profile and superior hypoglycemia profile from DEVOTE are directly relevant to this group, whose absolute cardiovascular risk is highest.

Women Who Should Think Carefully

• Women actively trying to conceive: Insulin degludec has no controlled human pregnancy data. Switching to an agent with a longer human safety record in pregnancy (NPH insulin or glargine, both of which have more gestational data) before conception is a reasonable discussion with your endocrinologist.
• Women with PCOS on high insulin doses: PCOS-driven insulin resistance can require large basal doses. Degludec U-200 (200 units/mL in the FlexTouch) accommodates high-dose requirements, but cost is a real barrier.
• Women with severe renal impairment: Dose adjustment guidance for eGFR <30 mL/min/1.73 m² exists, but data in this population are limited; older formulations have more observational data in dialysis-dependent patients.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, planning pregnancy, or breastfeeding.

Pregnancy

Insulin degludec carries no FDA pregnancy category under the current labeling system (categories A through X were retired in 2015), but the prescribing information states that there are no adequate and well-controlled studies in pregnant women. Animal reproduction studies showed fetal harm at doses 40 times the maximum recommended human dose. The drug is listed as Pregnancy Category Not Assigned, with the label stating use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Practically: insulin is essential for women with type 1 diabetes during pregnancy, and glucose control directly determines fetal outcomes. The question is not whether to use insulin but which basal insulin to use. NPH insulin has the longest gestational safety record and is the reference standard in many obstetric centers. Insulin glargine (Lantus, Basaglar) has substantially more observational human pregnancy data than degludec. A 2015 systematic review in Obstetrics and Gynecology found no increased risk of adverse maternal or neonatal outcomes with glargine in pregnancy compared with NPH, but no equivalent dataset exists for degludec at this time.

Recommendation: If you become pregnant while using Tresiba, do not stop insulin without medical guidance. Contact your endocrinologist and maternal-fetal medicine specialist immediately to discuss whether to continue degludec or transition to a better-studied basal insulin. This is a shared decision based on your glucose stability and the available data.

Postpartum and Lactation

Insulin is a large peptide (molecular weight approximately 5,800 daltons for the monomer). Like other insulins, degludec is expected to have minimal transfer into breast milk, and any that does transfer would be digested in the infant's gut rather than absorbed systemically. The prescribing information states that it is not known whether degludec is excreted in human milk. No controlled lactation studies exist. Insulin requirements typically drop sharply after delivery and shift again with breastfeeding, so close glucose monitoring and frequent dose adjustment are essential in the postpartum window regardless of which basal insulin you use.

Contraception

Insulin degludec is not a teratogen in the same category as, for example, isotretinoin, and it does not require mandatory contraception in non-pregnant women. However, given the absence of strong human pregnancy safety data, women of reproductive potential who are using degludec and not planning pregnancy should use reliable contraception and discuss switching to a better-studied basal insulin before attempting conception.

Insulin Degludec and Female-Specific Conditions

PCOS

Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, affecting 6 to 10 percent of this population. Hyperinsulinemia is a core driver of PCOS pathophysiology: elevated insulin stimulates ovarian androgen production, suppresses sex hormone binding globulin, and worsens anovulation. Most women with PCOS do not require exogenous insulin, but those with concurrent type 1 diabetes or advanced type 2 diabetes do. For PCOS patients on insulin, basal insulin choice matters primarily in terms of hypoglycemia risk and weight effect. Degludec has a modestly favorable weight profile compared with NPH but is broadly similar to glargine in head-to-head comparisons.

Perimenopause and Menopause

Estrogen withdrawal during perimenopause reduces insulin sensitivity and raises fasting glucose even in women without a formal diabetes diagnosis. For women who already have type 1 or type 2 diabetes, this transition can destabilize years of stable glycemic control. The unpredictability of the perimenopausal period makes a flat-profile basal insulin theoretically appealing. Menopausal hormone therapy (MHT), when appropriate, can itself improve insulin sensitivity in postmenopausal women with type 2 diabetes, an interaction that requires dose recalibration when MHT is started or stopped.

Hypothyroidism and Thyroid Disease

Women are five to eight times more likely than men to develop autoimmune thyroid disease. Hypothyroidism slows insulin clearance and can increase hypoglycemia risk; hyperthyroidism raises insulin requirements. Women with type 1 diabetes have a particularly high prevalence of concurrent autoimmune thyroid disease, estimated at 17 to 30 percent. Thyroid status should be checked at least annually in women on any basal insulin, as thyroid changes will affect dose requirements independent of the insulin chosen.

Cost, Access, and What to Ask Your Prescriber

Tresiba's list price in the United States is approximately $530 per box of five 3-mL FlexTouch pens (300 units per pen, 1,500 units per box). At a typical basal dose of 20 to 30 units per day, one box lasts 50 to 75 days. Out-of-pocket costs can exceed $3,000 per year for uninsured women.

Practical cost-mitigation options available now:

• Novo Nordisk Patient Assistance Program (PAP): Provides free Tresiba to qualifying uninsured and underinsured patients.
• Savings card (commercially insured): Novo Nordisk's My$99Insulin program caps monthly costs at $99 for eligible commercially insured patients.
• Medicare Part D $35 cap: The Inflation Reduction Act of 2022 capped insulin cost-sharing for Medicare Part D beneficiaries at $35 per month per covered insulin, effective January 2023.
• Clinical alternatives: If cost is prohibitive, glargine biosimilars (Semglee, Rezvoglar) are available at substantially lower prices and have comparable efficacy for most patients. The decision to switch should involve your prescriber.

Ask your prescriber directly: "Is the nocturnal hypoglycemia reduction with degludec clinically meaningful for my situation, or would a glargine biosimilar give me comparable results at lower cost?" That question frames the shared decision around your actual clinical needs, not brand preference.